DHG Pharmaceutical JSC (DHG)

Currency in VND
102,900.0
+400.0(+0.39%)
Real-time Data·

DHG Financial Summary

Key Ratios

P/E Ratio15.71
Price/Book3.6
Debt / Equity24.49%
Return on Equity21.57%
Dividend Yield13.17%
EBITDA1.09T
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of VND (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6,090.00%
Dividend Yield
13.17%
Industry Median 4.91%
Annualised payout
13,500.00
Paid unevenly
5-Years Growth
+20.11%
Growth Streak

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 106,900.0
(+3.89% Upside)

Earnings

Latest Release
May 28, 2025
EPS / Forecast
1,970.00 / --
Revenue / Forecast
1.19T / --
EPS Revisions
Last 90 days

FAQ

What were DHG Pharmaceutical JSC's earnings for the latest quarter?

The DHG Pharmaceutical JSC EPS (TTM) is 6,090.00. DHG Pharmaceutical JSC reported sales of 1,184,237.01, net income of 236,894.87, and EPS of 1,970.00 for the latest quarter.

What was DHG Pharmaceutical JSC's net income for the latest quarter?

DHG Pharmaceutical JSC's net income for the latest quarter was 236,894.87.

How did DHG Pharmaceutical JSC's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,194,544.78 in the previous quarter to 1,184,237.01 in the latest quarter, and net income moved from 266,239.85 to 236,894.87 compared to the previous quarter.

What is DHG Pharmaceutical JSC's net profit margin on a TTM basis?

DHG Pharmaceutical JSC's trailing twelve months (TTM) net profit margin is 15.95%.

How does DHG Pharmaceutical JSC's debt to equity ratio compare to industry standards?

DHG Pharmaceutical JSC's total debt-to-equity ratio is 24.49%.

What is DHG Pharmaceutical JSC's return on investment on a TTM basis?

DHG Pharmaceutical JSC's trailing twelve months (TTM) return on investment (ROI) is 21.57%.

Did DHG Pharmaceutical JSC gain or lose cash last quarter?

In the latest quarter, DHG Pharmaceutical JSC's net change in cash was -69,716.49 million.

What were DHG Pharmaceutical JSC's total assets and liabilities in the latest quarter?

As of the latest quarter, DHG Pharmaceutical JSC reported total assets of 5,495,044.46 million and total liabilities of 1,631,776.60 million.

How has DHG Pharmaceutical JSC's total revenue grown this year?

DHG Pharmaceutical JSC's total revenue was 1,194,544.78 in the previous quarter and 1,184,237.01 in the latest quarter.

What is DHG Pharmaceutical JSC's gross margin on a TTM basis?

DHG Pharmaceutical JSC's trailing twelve months (TTM) gross margin is 45.48%.

What was DHG Pharmaceutical JSC's revenue per share for the latest quarter?

DHG Pharmaceutical JSC's revenue per share for the latest quarter was 29,213.65.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.